Literature DB >> 23891872

Real-time duplex PCR for simultaneous HPV 16 and HPV 18 DNA quantitation.

Elise Jacquin1, Maëlle Saunier, Frédéric Mauny, Elisabeth Schwarz, Christiane Mougin, Jean-Luc Prétet.   

Abstract

HPV 16 and HPV 18 are responsible for more than 75% of cervical cancers and high HPV 16 loads are associated with both prevalent and incident lesions. The objective of the present study was to develop a method allowing the detection and quantitation of HPV 16 and 18 DNA to improve future strategies for cervical cancer screening. A duplex real-time PCR allowing the simultaneous quantitation of both HPV 16 and HPV 18 was carried out. Mixes of HPV 16 and HPV 18 whole genome plasmids were prepared to test a wide range of viral DNA concentrations. The values obtained for each mix of plasmids with the simplex and the duplex PCR were very close to the theoretical values except when a HPV type represented only 1:1000 genome equivalent or lower than the concurrent type. Cervical samples harboring HPV 16, HPV 18 or both types were tested by comparing the results with simplex and duplex real-time PCR assays. HPV 16 and HPV 18 genome titers were similar with the two assays. In conclusion, the real-time duplex PCR proved to be robust for HPV 16 and HPV 18 DNA quantitation.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  DNA quantitation; Duplex real-time PCR; HPV 16; HPV 18

Mesh:

Substances:

Year:  2013        PMID: 23891872     DOI: 10.1016/j.jviromet.2013.07.023

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  3 in total

1.  High levels of HPV16-L1 antibody but not HPV16 DNA load or integration predict oropharyngeal patient outcome: The Papillophar study.

Authors:  Jean-Luc Prétet; Véronique Dalstein; Antoine Touzé; Agnès Beby-Defaux; Patrick Soussan; Élise Jacquin; Philippe Birembaut; Christine Clavel; Christiane Mougin; Alexandra Rousseau; Jean Lacau Saint Guily
Journal:  Clin Exp Med       Date:  2022-02-23       Impact factor: 3.984

2.  Repurposing the Hybrid Capture 2 (HC2) screening test for whole-genome sequencing of human papillomaviruses.

Authors:  A Debernardi; W Jarassier; C Soret; C Mougin; S Alizon; I G Bravo; D Guenat; J L Prétet; Q Lepiller
Journal:  Arch Virol       Date:  2021-10-07       Impact factor: 2.574

3.  Development and interlaboratory agreement of real-time PCR for HPV16 quantification in liquid-based cervical samples.

Authors:  David Guenat; Véronique Dalstein; Frédéric Mauny; Maëlle Saunier; Jenny Briolat; Christine Clavel; Didier Riethmuller; Christiane Mougin; Jean-Luc Prétet
Journal:  Papillomavirus Res       Date:  2018-10-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.